Navigation Links
Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Date:1/16/2008

n partial onset seizures and 8.9% were free from any type of seizure over the treatment period, compared to 2.5% and 1.3% in the placebo group, respectively.

The study also found that extended-release levetiracetam tablets were generally well tolerated. The most common reported adverse events that occurred more frequently in the extended-release levetiracetam group were somnolence, influenza, nausea, nasopharyngitis, irritability, and dizziness.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting 40 million people worldwide including 2.5 million people in the U.S. It is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes, and effective classification guides treatment and prognosis. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or significant adverse side effects secondary to medication highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the U.S.: Keppra(R) (levetiracetam) tablets were first approved by the FDA in 1999 as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Since 1999, Keppra(R) has received several supplemental indications as adjunctive therapy for epilepsy, making it one of the few treatments approved to treat seizure types that together account for more than 80 percent of all seizures.

Important Safety Information

Keppra(R) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, myoclonic seizures in adults and adolescents 12 years of age and
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
2. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
3. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
4. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
5. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Critical Process Filtration, ... , today announces the expansion of their Technical ... Process Filtration now offers customers and potential customers ... to filter failure analyses (even for competitor filters) ... their hallmark services of system benchmarking and cost/performance ...
(Date:8/28/2014)... -- Rx Safes, Inc., the manufacturer of fingerprint recognition home ... new war on drugs to reduce prescription drug abuse, ... than 2,500 children a day experiment with prescription drugs ... accessed from unsecured medicine cabinets, closets and drawers.  While law ... Safes will address the new age drug dealer in ...
(Date:8/28/2014)... , Californie, 28 août 2014 ... annoncé aujourd,hui le début des inclusions ... étude  d,exemption des dispositifs expérimentaux (ou ... à évaluer l,innocuité et l,efficacité du ... Le docteur Adam Arthur , ...
Breaking Medicine Technology:Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2Rx Safes, Inc. Announces New War On Drugs 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 4
... 1, 2011 Hologic, Inc. (Hologic or ... developer, manufacturer and supplier of premium diagnostics, medical imaging ... needs of women, today announced it has acquired TCT ... in China, including Hologic,s ThinPrep Pap Test, related instruments ...
... Technology makes the PROFIT 200 list for the third ... Technology, headquartered in Toronto, has been included in the ... by PROFIT Magazine. Ranking Canada,s Fastest-Growing Companies by five-year ... successful growth companies. Published in the Summer issue of ...
Cached Medicine Technology:Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 2Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 3Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 4Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 5Claron Technology Makes the PROFIT 200 List for the Third Consecutive Year 2
(Date:8/28/2014)... Commercial growers all over the continent are waitlisted ... grow lights, which perform on par with 1000w HPS at ... lighting needs no cooling equipment and does not overheat the ... Factoring in that they never need bulbs changed, the internal ... year. , For many indoor growers, cooler room temperatures also ...
(Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
(Date:8/28/2014)... place glue directly on the nerve stumps, but this ... allows glue to easily invade the nerve ends. Ordinarily, ... insert the nerve ends into the conduit because the ... Liang and co-workers from the General Hospital of Chinese ... and defined the best parameters for its use through ...
(Date:8/28/2014)... of patients with stage III colon cancer had improved ... a new study in Gastroenterology ... Association. , When added to the standard chemotherapy treatment ... overall survival rates for patients with the CpG island ... to 20 percent of colorectal cancers. Patients with CIMP-negative ...
(Date:8/28/2014)... in the study who were on a class of ... as prescribed in the first six months. Patients from ... around the UK involved in the study. , Researchers ... Genomics at The University of Manchester, who led the ... known as ,non-adherence, reduced their effectiveness and may lead ...
Breaking Medicine News(10 mins):Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Drug shows promise for subset of stage III colon cancer patients 2Health News:Arthritis patients failing to take expensive medication, according to new research 2
... substantially reduce the risk of ovarian cancer in women ... research. Researchers say the magnitude of the risk reduction ... cancer has the highest fatality rate of all gynecological ... the strong predictors of developing ovarian cancer is a ...
... said on Thursday they were combining two new and experimental ... try to treat muscular dystrophy. Their early work has shown ... is years away. ,Writing in the journal Science, the ... Research Institute in Milan and the University of Rome said ...
... (GH) replacement therapy dosed to normalize IGF-I levels may be ... weight loss program for obese adults. ,The goal of ... retain lean body mass such as muscle,but what happens is ... they stop losing weight. Low levels of GH, known to ...
... rays -- two of which can cause severe skin ... Services at the University of California, the most dangerous ... shorter wavelengths and are primarily responsible for sunburn. Repeated ... immune system and can lead to melanoma and basal ...
... care what the compound microscope was to the biology ... worn on the body, such as a band around ... includes time spent lying down or sleeping, time spent ... ,Few medical advances in recent decades have had ...
... on Friday it expected to announce the removal of the island ... countries where new cases of the deadly virus had been reported ... the disease is 10 days, and twice that time is the ... situation over. ,The move, due to be announced at a ...
Cached Medicine News:Health News:Stem cells offer hope for muscular dystrophy 2Health News:Low-dose Growth Hormone (GH) with diet and exercise may help weight loss 2Health News:SARS-Free Taiwan to Mark End Phase of Global Fight 2
... Single use curved circular ... and titanium staples., ,The ... stapler is used throughout the ... of end-to-end, end-to-side and side-to-side ...
... The Scantibodies Calcitonin Immunoassay is a two-site ... calcitonin. Two different goat polyclonal antibodies to ... chromatography to be specific for well-defined regions ... quantitative determination of Calcitonin in human serum. ...
Calcitonin RIA Kit...
... IMAGE1 is the first completely digital camera ... in the field of endoscopic camera systems. ... the first time, facilitates the fully digital ... quality using an A/D converter, as well ...
Medicine Products: